Regeneron's Q2 Earnings Surge, But Q3 Profit Expected to Drop 33.5%
Regeneron Pharmaceuticals, Inc. (REGN), a biotech behemoth with a market cap of $59.1 billion, has witnessed its share price plummet by 44.9% over the past year, underperforming both the S&P 500 Index and the Health Care Select Sector SPDR Fund. Nevertheless, the company's recent earnings have surpassed expectations, driving a 2.5% surge in its share price following its Q2 results.
REGN's earnings per share of $12.89 in the previous quarter far exceeded consensus estimates by 60.5%. This robust performance was mirrored in its revenue, which grew by 3.6% year-over-year to $3.7 billion in Q2 2025, outpacing analyst expectations by 10.2%. However, looking forward, analysts predict a profit of $7.80 per share in Q3 2025, a substantial drop of 33.5% from the year-ago quarter. For the full fiscal year 2025, REGN is expected to report a profit of $32.36 per share, down 16.2% from fiscal 2024. Despite these anticipated declines, Wall Street analysts maintain a 'Moderate Buy' rating for REGN, with a mean price target of $729.85, suggesting a potential upside of 29.5% from current levels.
Regeneron Pharmaceuticals, Inc. is poised to unveil its fiscal Q3 earnings on October 28, 2025. While recent quarters have demonstrated strong earnings growth, analysts anticipate a decline in earnings per share for both Q3 2025 and the full fiscal year. Despite this, analysts remain bullish about REGN's prospects, retaining a 'Moderate Buy' rating and forecasting a substantial potential upside in its share price.
